多西他赛单药一线治疗晚期非小细胞肺癌临床研究

目的探讨多西他赛单药一线治疗晚期非小细胞肺癌临床疗效及不良反应。方法48例晚期非小细胞肺癌患者，多西他赛75m4g／lm2静脉滴注，第1天。21d为1个周期，治疗2～4个周期后评价临床疗效及不良反应。结果48例患者共化疗140个周期，中位化疗2．9个周期。RR为25．O％，DCR为56．3％，中位无进展生存期5．3个月，中位生存期8．6个月，1年生存率35．4％。不良反应以粒细胞减少、贫血、腹泻、脱发为主。结论多西他赛单药一线治疗晚期非小细胞肺癌临床疗效良好，患者耐受性较好。

Docetaxel as single-agent first-line treatment for advanced non-small cell lung cancer

Objective To investigate the clinical efficacy and adverse reactions of single-a- gent docetaxel first-line treatment for advanced non-small cell lung cancer （NSCLC）. Methods Forty-eight advanced NSCLC patients were included in the study who received intravenous infusion of docetaxel, 75 rag/m2, dl. One treatment cycle included 21d. The clinical efficacy and adverse reactions were evaluated after 2 to 4 cycles. Results All the 48 patients received 140 cycles of chemotherapy with a median of 2.9. RR was 25.0 %, DCR was56.3 %, the median progression- free survival period was 5.3 months, median survival period was 8.6 months, and one-year survival rate was 35.4 %. Adverse reactions mainly included neutropenia, anemia, diarrhea, and hair loss. Conclusion Docetaxel single-agent first-line treatment is effective in treating advanced NSCLC with good tolerance. WTSHZI]